British robotics company CMR Surgical announced a $ 600 million Series D this morning. This latest round, led by Softbank’s Vision Fund 2 and co-led by Ally Bridge Group, joins the $ 384.8 million already raised by the Cambridge company. He values the company at $ 3 billion.
CMR’s flagship product is Versius. The robotic system is designed to perform minimally invasive keyhole surgery, primarily focused on serious conditions such as bowel disease or bowel cancer. The platform has been used around the world and has so far been involved in 1,000 surgeries, according to CMR figures.
Four National Health Service (NHS) hospitals in the UK have used the surgical platform, as well as many other locations in Europe, India, the Middle East and Australia. As RMC notes, the pandemic has resulted in a massive backlog of surgeries.
Like many other robotic surgical platforms, one of Versius’ main draws is its sense of accessibility, which essentially helps level the playing field for complex procedures. The system is modular and portable compared to a number of competitors, further increasing this accessibility. The company says the funding will be used to accelerate the platform’s global deployment.
“This latest funding provides CMR with significant funds to accelerate our mission of bringing Versius to hospitals around the world, while providing complete flexibility to achieve our goals,” CEO Per Vegard Nerseth said in a statement related to the news. “This significant capital injection which now values us at $ 3 billion reflects not only the level of interest we have seen in our product, but also the scale of the business, and will allow for significant technological developments and expansion. global. “
In recent times, surgical robotics has become an increasingly popular category for venture capital funds. Recent rounds include $ 96 million for Memic, $ 10 million for ForSight and $ 15 million for Activ. However, even by those standards, this is a huge turn for the category.